Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 3,444 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neoplasms,Colorectal Clear all
Completed Not applicable Interventional

Hybrid Capture 2 Human Papiloma Virus (HPV) High-Risk Anal DNA Test

NCT01104181
View directory record Official record
Conditions
Anal Canal HPV Infection Diagnosis, Anal Dysplasia Diagnosis, Anal Cancer
Interventions
HC2 collection kit with a swab or brush
Device
Lead sponsor
Laser Surgery Care
Other
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 22, 2026, 2:43 AM EDT
Terminated Phase 2 Interventional Results available

A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer

NCT02402036
View directory record Official record
Conditions
Colon Cancer
Interventions
Regorafenib
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 22, 2026, 2:43 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

NCT07292298
View directory record Official record
Conditions
Rectal Adenocarcinoma, Rectal Cancer
Interventions
High Rare Dose Rectal Brachytherapy Boost
Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Aurora, Colorado • Rochester, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 22, 2026, 2:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Confocal Probe-based Endoscopic Imaging, Colorectal Cancer, Gastrointestinal (GI) Pathologies

NCT00874263
View directory record Official record
Conditions
Colonic Polyps, Esophageal Diseases
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 22, 2026, 2:43 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Evaluation of Stool Tagging for Improved Patient Compliance

NCT00124163
View directory record Official record
Conditions
Colon Cancer, Polyps
Interventions
Imaging procedure of CT colonography
Procedure
Lead sponsor
Center for Diagnostic Imaging
Other
Eligibility
45 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 2, 2006 · Synced Oct 22, 2026, 2:43 AM EDT
Recruiting Phase 1Phase 2 Interventional

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

NCT07189871
View directory record Official record
Conditions
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC), Sarcoma
Interventions
177Lu-BetaBart, BetaBart + unlabeled BetaBart
Drug
Lead sponsor
Radiopharm Theranostics, Ltd
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Dothan, Alabama • Grand Rapids, Michigan • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Not applicable Interventional Results available

CryoBalloon Ablation for Treatment of Duodenal Adenomas

NCT03847636
View directory record Official record
Conditions
Duodenal Adenomas, Familial Adenomatous Polyposis
Interventions
CryoBalloon ablation
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
4
States / cities
Baltimore, Maryland • Manhasset, New York • Danville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 22, 2026, 2:43 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer

NCT02038699
View directory record Official record
Conditions
Advanced Glioblastoma, Advanced Colorectal Cancer, Advanced Triple-negative Breast Cancer, Advanced Non-small Cell Lung Cancer
Interventions
ONC201
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 22, 2026, 2:43 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

NCT04895709
View directory record Official record
Conditions
Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
Interventions
BMS-986340, BMS-936558-01, Docetaxel, Pumitamig
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
11
States / cities
Clovis, California • Los Angeles, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

NCT00467844
View directory record Official record
Conditions
Cachexia
Interventions
GTx-024, Placebo
Drug
Lead sponsor
GTx
Industry
Eligibility
Not listed
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
50
States / cities
Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 22, 2026, 2:43 AM EDT
Not yet recruiting No phase listed Observational

A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment

NCT07814872
View directory record Official record
Conditions
Neoplasms (Cancer / Tumors), Colorectal Neoplasms, Lung Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Pancreatic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Glioma, Ovarian Neoplasms, Stomach Neoplasms
Interventions
Not listed
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
Not listed
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 22, 2026, 2:43 AM EDT
Terminated Phase 1 Interventional

Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver

NCT02110953
View directory record Official record
Conditions
Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
irinotecan-eluting beads, hepatic artery embolization
Combination Product · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer

NCT00828984
View directory record Official record
Conditions
Adenomatous Polyp, Colorectal Carcinoma
Interventions
macrogol 3350-based oral osmotic laxative, Placebo, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Chicago, Illinois • Evanston, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of Using Computerized Education to Increase Patients' Confidence in Their Ability to Be Screened for Colon Cancer

NCT00273585
View directory record Official record
Conditions
Colorectal Cancer Screening
Interventions
Personally-tailored educational software program
Device
Lead sponsor
University of California, Davis
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2006 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

NCT03872947
View directory record Official record
Conditions
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
Biological · Drug
Lead sponsor
Toray Industries, Inc
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 22, 2026, 2:43 AM EDT
Enrolling by invitation Not applicable Interventional

Postbiotics for Mitigation of Postoperative Dysbiosis in Gastrointestinal Cancer Surgery

NCT07050485
View directory record Official record
Conditions
Colon Cancer, Gastrointestinal Cancer
Interventions
PoZibio, Inert placebo
Dietary Supplement
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 22, 2026, 2:43 AM EDT
Completed No phase listed Observational

B-Receptor Signaling in Cardiomyopathy

NCT01135849
View directory record Official record
Conditions
Carcinomas, Amyloidosis, Anal Cancer, Anemia, Cholangiocarcinoma of the Extrahepatic Bile Duct, Transitional Cell Carcinoma of Bladder, Bone Marrow Transplant Failure, Bone Cancer, Cancer of Brain and Nervous System, Breast Cancer, Carcinoma of the Large Intestine, Endocrine Cancer, Esophageal Cancer, Eye Cancer, Gall Bladder Cancer, Gastric (Stomach) Cancer, Gastrooesophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Gynecologic Cancers, Head and Neck Cancers, Hepatobiliary Neoplasm, Kidney (Renal Cell) Cancer, Leukemia, Lung Cancer, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mesothelioma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Neuroendocrine Tumors, Myeloproliferative Disorders, Pancreatic Cancer, Prostate Cancer, Skin Cancer, Soft Tissue Sarcoma, Testicular Cancer, Thymus Cancer, Thyroid Cancer
Interventions
Not listed
Lead sponsor
Daniel Bernstein
Other
Eligibility
Up to 40 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 22, 2026, 2:43 AM EDT
Recruiting Phase 1 Interventional

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT04222413
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer, Malignant Peripheral Nerve Sheath Tumor, Colorectal Neoplasms
Interventions
Metarrestin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Fairway, Kansas • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 1Phase 2 Interventional

Improving Fecal Occult Blood Test Completion Rates Among Veterans

NCT01516489
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Stage 1, Stage 2
Behavioral
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
Male only
Enrollment
1,549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Oct 22, 2026, 2:43 AM EDT
Terminated Phase 1Phase 2 Interventional

Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer

NCT00036517
View directory record Official record
Conditions
Colorectal Neoplasms, Diarrhea
Interventions
PHY906
Drug
Lead sponsor
PhytoCeutica
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
3
States / cities
West Haven, Connecticut • New York, New York • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 2:43 AM EDT
Terminated No phase listed Observational

Do Patients With Colorectal Cancer Understand That Their Family is at Risk?

NCT00145860
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 22, 2026, 2:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Prevention of Colorectal Cancer Through Multiomics Blood Testing

NCT04369053
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer, Colon Neoplasm, Colon Diseases, Colon Lesion, Colon Polyp, Colorectal Cancer, Polyp, Adenoma, Rectal Diseases, Gastrointestinal Tract Cancers
Interventions
Freenome test
Diagnostic Test
Lead sponsor
Freenome Holdings Inc.
Industry
Eligibility
45 Years to 85 Years
Enrollment
48,995 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
147
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 122 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy

NCT00967616
View directory record Official record
Conditions
Colorectal Cancer, Neoplasms, Colorectal
Interventions
CS7017, irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
Beverly Hills, California • Fullerton, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Oct 22, 2026, 2:43 AM EDT
Recruiting Phase 2 Interventional

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

NCT04899908
View directory record Official record
Conditions
Brain Cancer, Brain Metastases, Melanoma, Lung Cancer, Breast Cancer, HER2-positive Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, SRS, SRT, Whole Brain Radiation, Stereotactic Radiation, AGuIX, Nanoparticle, Cystic, Brain Tumor
Interventions
Stereotactic Radiation, AGuIX gadolinium-based nanoparticles, Placebo
Radiation · Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 2:43 AM EDT